Autopsy report · NCT00520975

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

“Closed early due to slow accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 7 years 11 months before it stopped.
• 96 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

National Cancer Institute (NCI)

Sponsor type

US National Institutes of Health

Conditions

Breast Carcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer

Interventions

Bevacizumab; Carboplatin; Paclitaxel; Placebo; Trastuzumab

Participants

96

Sites

373

Countries

United States

Trials that died the same way

• Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
  “Closed early due to low accrual.” (90% match in meaning)
• Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
  “Closed due to very slow accrual” (89% match in meaning)
• Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL
  “Closed early due to poor accrual.” (89% match in meaning)
• Pemetrexed Plus Gemcitabine in Renal Cell Cancer
  “Closed early for poor accrual.” (85% match in meaning)
• Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients
  “Closed prematurely because the accrual was not achieved” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.